Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;57(2):1259-1280.
doi: 10.1007/s12035-019-01820-5. Epub 2019 Nov 12.

Molecular Approaches for the Treatment of Pompe Disease

Anita Sofia Bellotti  1 , Luca Andreoli  1 , Dario Ronchi  1 , Nereo Bresolin  1   2 , Giacomo P Comi  1   3 , Stefania Corti  4   5
Affiliations
Free article
Review

Molecular Approaches for the Treatment of Pompe Disease

Anita Sofia Bellotti et al. Mol Neurobiol. 2020 Feb.
Free article

Abstract

Glycogen storage disease type II (GSDII, Pompe disease) is a rare metabolic disorder caused by a deficiency of acid alpha-glucosidase (GAA), an enzyme localized within lysosomes that is solely responsible for glycogen degradation in this compartment. The manifestations of GSDII are heterogeneous but are classified as early or late onset. The natural course of early-onset Pompe disease (EOPD) is severe and rapidly fatal if left untreated. Currently, one therapeutic approach, namely, enzyme replacement therapy, is available, but advances in molecular medicine approaches hold promise for even more effective therapeutic strategies. These approaches, which we review here, comprise splicing modification by antisense oligonucleotides, chaperone therapy, stop codon readthrough therapy, and the use of viral vectors to introduce wild-type genes. Considering the high rate at which innovations are translated from bench to bedside, it is reasonable to expect substantial improvements in the treatment of this illness in the foreseeable future.

Keywords: Alpha-glucosidase (GAA); Antisense oligonucleotides; GSDII; Gene therapy; Molecular therapy; Pompe disease; Therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mol Ther. 2005 Jan;11(1):57-65 - PubMed
    1. JCI Insight. 2019 Mar 7;4(5): - PubMed
    1. Hum Mol Genet. 2015 Feb 1;24(3):625-36 - PubMed
    1. Mol Ther. 2014 Apr;22(4):702-12 - PubMed
    1. Neuropathol Appl Neurobiol. 2018 Aug;44(5):449-462 - PubMed

MeSH terms

LinkOut - more resources